We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


How To Ensure Lipid Nanoparticle (LNP) Quality With Adam Crowe

Lipid nanoparticles (LNPs) are widely used vehicles for oligonucleotide-based therapeutics and vaccines, which are composed of helper lipids, PEGylated lipids and ionizable lipids. Ionizable lipids are susceptible to oxidation to various degrees. These oxidative impurities can covalently bind to the mRNA and result in a loss of function, even if present at very low amounts (<0.1%). Some common analytical assays cannot detect these mRNA-lipid impurities. Furthermore, not all oxidation impurities pose the same risk of impacting the function of the fragile genetic cargo.

In this episode of Teach Me in 10, we are joined by Adam Crowe who is a manager of analytical development at Precision NanoSystems Inc.

Adam will highlight how to overcome the challenges of attaining detailed characterization and quantitation of related impurities including the ability to differentiate between different oxidative species in order to develop safe and successful genetic products.

Further reading:

Brought to you by